Drug intelligence / Profile preview

17alpha-methyl-5alpha-androstane-3alpha,17beta-diol

Development stage: Unknown
Modality: Small Molecules

Overview

BA-2664 (also known as 17alpha-methyl-5alpha-androstane-3alpha,17beta-diol) is a synthetic androgen and anabolic steroid. It is a methylated derivative of dihydrotestosterone (DHT) and belongs to the class of C19 steroid hormones. These compounds are known to favor the development of masculine characteristics by acting as agonists at androgen receptors. BA-2664 has been described primarily in research contexts and does not have established clinical use or approved indications[1][2][3][4].

Other names: 17alpha-Methyl-5alpha-androstane-3alpha,17beta-diolUNII-56K8Z5YS2ZUNII56K8Z5YS2ZUNII 56K8Z5YS2Z56K8Z5YS2ZAndrostane-3,17-diol 17-methyl (3alpha,5alpha,17beta)17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on 17alpha-methyl-5alpha-androstane-3alpha,17beta-diol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 17alpha-methyl-5alpha-androstane-3alpha,17beta-diol.

Explore the full profile